Since the first report of a young girl affected by sickle cell anemia, treated successfully by bone marrow transplantation (BMT) for acute myeloid leukemia, more than 200 patients have been transplanted worldwide for sickle cell anemia. The disease-free survival (DFS) is good (80-85% in several seri
Non-HLA immunogenetics in hematopoietic stem cell transplantation
β Scribed by Anne M Dickinson; Dominique Charron
- Publisher
- Elsevier Science
- Year
- 2005
- Tongue
- English
- Weight
- 168 KB
- Volume
- 17
- Category
- Article
- ISSN
- 0952-7915
No coin nor oath required. For personal study only.
β¦ Synopsis
Hematopoietic stem cell transplantation (HSCT) provides a unique environment in which to evaluate the role of immunogenetics of both the donor and the recipient to success of the procedure. The central role of HLA matching in HSCT has been established; however, recipients of allogeneic HSCT incur the risk of graft versus host disease (GVHD) even when the donor is a sibling who shares the major histocompatibility genes. Therefore, the perfect HLA match does not represent the optimal genetic make up. Other genetic systems operate and affect the various outcomes of HSCT, including GVHD, infections, transplant-related mortality, and overall survival. Minor histocompatibility antigens contribute to the control of GVHD as well as graft versus leukaemia reactions. In addition, genes controlling inflammatory processes, including cytokines, chemokines and their receptors, can modulate GVHD, and genes from both arms of the immune response (innate and adaptive) are strong candidates for susceptibility factors to infections in allogenic transplantation.
π SIMILAR VOLUMES
Although the key role of MHC-restricted T lymphocytes in hematopoietic stem cell transplantation (HSCT) has been known for a long time, recent data have focused on complementary or alternative effector cell populations, and in particular on NK cells. Spontaneously generated NK cell alloreactivity fr
A 43-year-old man with acute lymphoblastic leukemia was treated with three cycles of hyper-CVAD (hyper fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone) followed by allogeneic hematopoietic stem cell transplantation (HCT) from a sibling. Six months later, the patient presen